Eli Lilly (LLY -1.1%), Amylin (AMLN -24.7%) and Alkermes (ALKS -14.9%) provide top-line results...

|About: Eli Lilly and Company (LLY)|By:, SA News Editor

Eli Lilly (LLY -1.1%), Amylin (AMLN -24.7%) and Alkermes (ALKS -14.9%) provide top-line results from a head-to-head study, showing investigational diabetes therapy Bydureon didn't meet the pre-specified primary endpoint of non-inferiority to Victoza (NVO +5%). (PR)